Screener
Ginkgo Bioworks DNA Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -259.9%-118pp | -221.9%-18.3pp | -200.5%+46.1pp | -207.9%+83.1pp | -141.7%+328pp | |
| Net margin | -260%-110pp | -232.6%-25.0pp | -209.1%+31.9pp | -212.2%+86.6pp | -149.9%+337pp | |
| Returns | ||||||
| Return on equity | -56.3%-12.7pp | -55.8%+1.9pp | -51.1%+9.3pp | -50%+13.5pp | -43.6%+33.2pp | |
| Return on invested capital | -40.3%+15.3pp | -41.7%+45.5pp | -45.6%+75.0pp | -47.3%+63.6pp | -55.6%+113pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×+0.1× | |
| Liquidity | ||||||
| Current ratio | 4.6×-0.8× | 5.2×+0.3× | 4.9×-0.7× | 4.4×-1.4× | 5.4×+0.7× | |
| Leverage | ||||||
| Debt-to-equity | 1×+0.3× | 0.9×+0.3× | 0.9×+0.2× | 0.8×+0.2× | 0.7×+0.4× | |
| Valuation | ||||||
| Market capitalization | $520.64M-26.0% | $379.6M+14.8% | $503.5M-10.8% | $863.13M+90.6% | $537.91M-27.2% | |
| Price / sales | 4.7×+1.3× | 2.9×+1.4× | 3.4×+0.9× | 5.4×+3.3× | 2.6×-1.5× | |
| Price / book | 1.2×+0.1× | 0.9×+0.3× | 1×+0.2× | 1.5×+1.0× | 0.9×0.0× |
FAQ
- What are Ginkgo Bioworks's profit margins?
- Ginkgo Bioworks (DNA) runs a 91.8% gross margin and a -259.9% operating margin, with a -260.0% net margin.
- Where do Ginkgo Bioworks's ratios come from?
- Every ratio is computed from Ginkgo Bioworks's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
